Received May 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Y012508 | OT |
No adverse event; HCP reports female patient received her second dose of GARDASIL 9 early. HCP states second dose administered on 2/5/2025 and was due on 2/21/2025. No adverse effects reported. No other information provided. No additional AE. No PQC.; This spontaneous report was received from a Nurse and refers to a 33-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 05-FEB -2025, the patient was early vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), (lot #Y012508, expiration date: 01-JAN-2027), dose number 2, Single Dose, administered by Unknown route for Prophylaxis. The second dose was due on 21-FEB-2025 (Inappropriate schedule of product administration). No adverse effects were reported.